BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 2250704)

  • 1. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.
    Strasser A; Harris AW; Bath ML; Cory S
    Nature; 1990 Nov; 348(6299):331-3. PubMed ID: 2250704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The transgenic window on lymphoid malignancy.
    Adams JM; Harris AW; Vaux DL; Alexander WS; Rosenbaum H; Klinken SP; Strasser A; Bath ML; McNeall J; Cory S
    Princess Takamatsu Symp; 1989; 20():297-309. PubMed ID: 2518688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moloney murine leukemia virus infection accelerates lymphomagenesis in E mu-bcl-2 transgenic mice.
    Shinto Y; Morimoto M; Katsumata M; Uchida A; Aozasa K; Okamoto M; Kurosawa T; Ochi T; Greene MI; Tsujimoto Y
    Oncogene; 1995 Nov; 11(9):1729-36. PubMed ID: 7478600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes.
    Zörnig M; Busch G; Beneke R; Gulbins E; Lang F; Ma A; Korsmeyer S; Möröy T
    Oncogene; 1995 Nov; 11(10):2165-74. PubMed ID: 7478538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells.
    Vaux DL; Cory S; Adams JM
    Nature; 1988 Sep; 335(6189):440-2. PubMed ID: 3262202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo.
    Marin MC; Hsu B; Stephens LC; Brisbay S; McDonnell TJ
    Exp Cell Res; 1995 Apr; 217(2):240-7. PubMed ID: 7698223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
    Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
    Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells.
    Strasser A; Harris AW; Cory S
    Oncogene; 1993 Jan; 8(1):1-9. PubMed ID: 8423986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines.
    Capaccioli S; Quattrone A; Schiavone N; Calastretti A; Copreni E; Bevilacqua A; Canti G; Gong L; Morelli S; Nicolin A
    Oncogene; 1996 Jul; 13(1):105-15. PubMed ID: 8700536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights from transgenic mice regarding the role of bcl-2 in normal and neoplastic lymphoid cells.
    Cory S; Harris AW; Strasser A
    Philos Trans R Soc Lond B Biol Sci; 1994 Aug; 345(1313):289-95. PubMed ID: 7846127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent activation of c-myc and inactivation of bcl-2 by chromosomal translocation in a lymphoblastic lymphoma cell line.
    Kiem HP; Nourse J; Saltman DL; Blume KG; Cleary ML
    Oncogene; 1990 Dec; 5(12):1815-9. PubMed ID: 2284100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth of E mu-myc transgenic B-lymphoid cells in vitro and their evolution toward autonomy.
    Langdon WY; Harris AW; Cory S
    Oncogene Res; 1988; 3(3):271-9. PubMed ID: 3144697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death.
    Hockenbery D; Nuñez G; Milliman C; Schreiber RD; Korsmeyer SJ
    Nature; 1990 Nov; 348(6299):334-6. PubMed ID: 2250705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-B-cell leukemia with a t(8; 14) and a t(14; 18) translocation is preceded by follicular lymphoma.
    Gauwerky CE; Hoxie J; Nowell PC; Croce CM
    Oncogene; 1988 May; 2(5):431-5. PubMed ID: 3131717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The bcl-2 oncogene and apoptosis.
    Hockenbery DM
    Semin Immunol; 1992 Dec; 4(6):413-20. PubMed ID: 1286168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
    Yu D; Thomas-Tikhonenko A
    Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
    Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
    Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells.
    Duan H; Heckman CA; Boxer LM
    Oncogene; 2007 Apr; 26(18):2635-41. PubMed ID: 17043638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu).
    Palomo C; Zou X; Nicholson IC; Bützler C; Brüggemann M
    Cancer Res; 1999 Nov; 59(21):5625-8. PubMed ID: 10554044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice.
    Möröy T; Verbeek S; Ma A; Achacoso P; Berns A; Alt F
    Oncogene; 1991 Nov; 6(11):1941-8. PubMed ID: 1658705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.